Market Cap 3.38B
Revenue (ttm) 0.00
Net Income (ttm) -175.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.21
Volume 603,100
Avg Vol 1,926,696
Day's Range N/A - N/A
Shares Out 53.15M
Stochastic %K 10%
Beta -2.75
Analysts Strong Sell
Price Target $119.82

Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 213 8444
Fax: 650 213 8383
Website: soleno.life
Address:
100 Marine Parkway, Suite 400, Redwood City, United States
Damian23
Damian23 Oct. 23 at 2:33 PM
$SLNO Pricing: The company and analysts confirm Vykat XR is priced at roughly $466,000 per patient per year in the U.S. (at $5.92/mg, mean 61 kg).​ Patient population (TAM): U.S. diagnosed PWS population spans ~10,000; EU5 (main European markets) add ~9,000.​ Gross TAM: 19,000 x $466,000 = $8.X.85 billion maximum annual sales if every eligible patient is treated at full U.S. price. Serviceable Addressable Market (SAM): Real-world adoption is lower—assume 25% penetration by 2028, or ~4,750 patients worldwide. Peak sales calculation: 4,750 x $466,000 = $2.X.21 billion in gross peak annual sales. Discount for net price: Real net after discounts/rebates likely 80% of list, so $2.X.21B x 0.8 = $1.X.77 billion in net peak annual sales. Analyst consensus check: Most analysts (Stifel, Visible Alpha, Investing) project U.S. peak sales from $1.X.1B to $2B, worldwide $2.X.0–2.8B, which brackets this estimate.​
1 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
CrispDry
CrispDry Oct. 21 at 7:38 PM
$SLNO I cant wait until Nov 4.
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 8:33 PM
Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO
0 · Reply
RunnerSignals
RunnerSignals Oct. 16 at 8:31 PM
Comeback Kings on the Move! $SLNO $FATE $SION hit the lows, bounced back, and finished strong!
0 · Reply
topstockalerts
topstockalerts Oct. 16 at 6:37 PM
$SLNO & it’s green..
0 · Reply
Zzzquil
Zzzquil Oct. 16 at 5:59 PM
$SLNO https://x.com/markflowchatter/status/1978881293816345055?s=46&t=35gXT27eTg2t7SPu9qB-oA
1 · Reply
CrispDry
CrispDry Oct. 16 at 5:59 PM
$SLNO so exhausted by all the up and down $SRPT
0 · Reply
OptionRunners
OptionRunners Oct. 16 at 5:48 PM
$SLNO spiking
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 16 at 5:48 PM
$SLNO maybe it's scorpion finally covering
0 · Reply
Latest News on SLNO
Soleno: Blockbuster Launch In Progress

Oct 11, 2025, 8:45 AM EDT - 14 days ago

Soleno: Blockbuster Launch In Progress


Soleno Therapeutics Announces VYKAT(TM) XR Launch

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch


Damian23
Damian23 Oct. 23 at 2:33 PM
$SLNO Pricing: The company and analysts confirm Vykat XR is priced at roughly $466,000 per patient per year in the U.S. (at $5.92/mg, mean 61 kg).​ Patient population (TAM): U.S. diagnosed PWS population spans ~10,000; EU5 (main European markets) add ~9,000.​ Gross TAM: 19,000 x $466,000 = $8.X.85 billion maximum annual sales if every eligible patient is treated at full U.S. price. Serviceable Addressable Market (SAM): Real-world adoption is lower—assume 25% penetration by 2028, or ~4,750 patients worldwide. Peak sales calculation: 4,750 x $466,000 = $2.X.21 billion in gross peak annual sales. Discount for net price: Real net after discounts/rebates likely 80% of list, so $2.X.21B x 0.8 = $1.X.77 billion in net peak annual sales. Analyst consensus check: Most analysts (Stifel, Visible Alpha, Investing) project U.S. peak sales from $1.X.1B to $2B, worldwide $2.X.0–2.8B, which brackets this estimate.​
1 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
CrispDry
CrispDry Oct. 21 at 7:38 PM
$SLNO I cant wait until Nov 4.
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 19 at 8:33 PM
Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO
0 · Reply
RunnerSignals
RunnerSignals Oct. 16 at 8:31 PM
Comeback Kings on the Move! $SLNO $FATE $SION hit the lows, bounced back, and finished strong!
0 · Reply
topstockalerts
topstockalerts Oct. 16 at 6:37 PM
$SLNO & it’s green..
0 · Reply
Zzzquil
Zzzquil Oct. 16 at 5:59 PM
$SLNO https://x.com/markflowchatter/status/1978881293816345055?s=46&t=35gXT27eTg2t7SPu9qB-oA
1 · Reply
CrispDry
CrispDry Oct. 16 at 5:59 PM
$SLNO so exhausted by all the up and down $SRPT
0 · Reply
OptionRunners
OptionRunners Oct. 16 at 5:48 PM
$SLNO spiking
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 16 at 5:48 PM
$SLNO maybe it's scorpion finally covering
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 16 at 5:48 PM
$SLNO Spike 👀
0 · Reply
OptionRunners
OptionRunners Oct. 10 at 7:34 PM
$SLNO Buyer of the November 21st $65/$95 call spreads 5,000 times for $6.85. Looks to be adding here, check the change in OI for confirmation.
0 · Reply
WarrenPsnik
WarrenPsnik Oct. 9 at 11:44 PM
$SLNO How now brown cow? :)
0 · Reply
Jabed206
Jabed206 Oct. 8 at 11:34 PM
$SLNO when is earnings?
0 · Reply
OptionRunners
OptionRunners Oct. 8 at 5:01 PM
$SLNO Buyer of the November 21st $65/$95 call spreads 5,000 times for $6.20
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 7 at 4:25 PM
$CRMD $GERN $IBRX $KALV $SLNO this is a great point. Holding Kalvista but even as a novel oral approval in a rare disease, this company is not getting the respect that an oncology launch would
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 7 at 2:03 PM
$SLNO Starter
0 · Reply
Quantumup
Quantumup Oct. 7 at 10:36 AM
Goldman Sachs🏁 $SLNO's at Buy-$125 and said, 'We See Vykat XR Becoming A Mainstay Treatment For Prader-Willi Syndrome (PWS)'—sees attractive entry point given recent volatility. $AARD $RYTM Goldman Sachs additionally said:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 7 at 1:44 AM
To us it appears that since commercial-stage oncology trades at significantly lower revenue multiples than non-oncology, oncology offers the better risk v. reward profile now that the XBI is nearing multi-year highs. Bios in both peer groups have near-tern data reads that may manifest in higher/lower revenues depending on the outcomes ($GERN $IBRX) Are we wrong? This is not investment advice. $KALV $CRMD $SLNO
0 · Reply
WarrenPsnik
WarrenPsnik Oct. 6 at 6:59 PM
$SLNO Added here …
0 · Reply
Drashkawisha
Drashkawisha Oct. 6 at 5:10 PM
$SLNO $SLNO - The December "poker bet". PDUFA on 12/19 for DCCR in Prader-Willi Syndrome (PWS). The Case: Bull: Huge unmet need. The original Phase 3 trial failed due to a strong placebo effect, but the long-term extension data was strong. The FDA accepted the resubmission based on a "totality of evidence" argument without requiring a new trial – a rare sign of regulatory flexibility. Bear: The data package remains messy and is based on a failed pivotal study. Plus, they have a prior CRL (rejection). Extremely high risk. Bottom Line: A pure bet that the FDA will prioritize the unmet medical need and accept a non-standard data package, especially after giving them an initial green light to submit. One of the highest risk/reward setups on the market.
1 · Reply
Hottehueh
Hottehueh Oct. 3 at 5:07 PM
$SLNO added some 60/75 dec call spreads. 4x if 75 or above in dec...
0 · Reply